Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Short term Debt (2023 - 2025)

Historic Short term Debt for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • Profound Medical's Short term Debt changed N/A to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 1744.3% down from last year.
  • According to the latest figures from Q3 2025, Profound Medical's Short term Debt is $4.5 million.
  • Profound Medical's Short term Debt's 5-year high stood at $4.5 million during Q3 2025, with a 5-year trough of $1.7 million in Q4 2024.
  • For the 3-year period, Profound Medical's Short term Debt averaged around $2.8 million, with its median value being $2.1 million (2023).
  • Examining YoY changes over the last 5 years, Profound Medical's Short term Debt showed a top increase of 1744.3% in 2024 and a maximum decrease of 1744.3% in 2024.
  • Quarter analysis of 3 years shows Profound Medical's Short term Debt stood at $2.1 million in 2023, then decreased by 17.44% to $1.7 million in 2024, then skyrocketed by 157.92% to $4.5 million in 2025.
  • Its Short term Debt stands at $4.5 million for Q3 2025, versus $1.7 million for Q4 2024 and $2.1 million for Q4 2023.